论文部分内容阅读
目的比较舒利迭(沙美特罗/丙酸氟替卡松)联合孟鲁司特治疗咳嗽变异性哮喘(CVA)与单用舒利迭治疗的临床疗效。方法将36例CVA患者随机分成两组,分别给予舒利迭,联合孟鲁司特及单用舒利迭治疗8周,观察疗效。结果两组治疗前后咳嗽症状评分及肺功能指标均改善(P<0.05),且观察组优于对照组(P<0.05)。结论舒利迭联合孟鲁司特较单用舒利迭治疗CVA能更好改善临床症状及肺功能。
Objective To compare the clinical efficacy of seretide (salmeterol / fluticasone propionate) and montelukast in the treatment of cough variant asthma (CVA) and seretide alone. Methods Thirty-six patients with CVA were randomly divided into two groups and were given seretide, montelukast and seretide alone for 8 weeks respectively. The curative effect was observed. Results Before and after treatment, the cough symptom scores and pulmonary function indexes were improved (P <0.05), and the observation group was better than the control group (P <0.05). Conclusion The combination of seretide and montelukast can improve the clinical symptoms and lung function better than CVA alone.